About ParAllele BioScience
ParAllele BioScience is a company based in San Francisco (United States) founded in 2001 by Malek Faham was acquired by Affymetrix in May 2005. ParAllele BioScience has raised $22.5 million across 2 funding rounds from investors including Abingworth, Affymetrix and Mohr Davidow Ventures. ParAllele BioScience operates in a competitive market with competitors including GSK, Metabolon, Avidity Biosciences, Sutro Biopharma and Maze Therapeutics, among others.
- Headquarter San Francisco, United States
- Founders Malek Faham
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$22.5 M (USD)
in 2 rounds
-
Latest Funding Round
$6 M (USD), Debt – Convertible
Apr 14, 2005
-
Investors
Abingworth
& 4 more
-
Employee Count
Not available
-
Acquired by
Affymetrix
(May 31, 2005)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ParAllele BioScience
ParAllele BioScience has successfully raised a total of $22.5M across 2 strategic funding rounds. The most recent funding activity was a Debt – Convertible round of $6 million completed in April 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ParAllele BioScience
ParAllele BioScience has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Abingworth, Affymetrix and Mohr Davidow Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are managed in technology and healthcare sectors by this firm.
|
Locked | Locked | Locked | |
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked | |
|
Venture capital investments in technology startups and entrepreneurs.
|
Locked | Locked | Locked |
Investor details for ParAllele BioScience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ParAllele BioScience
Investment portfolio details for ParAllele BioScience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ParAllele BioScience
Detailed financials for ParAllele BioScience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Parallele Bioscience Comparisons
Peer comparison for ParAllele BioScience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ParAllele BioScience
ParAllele BioScience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Metabolon, Avidity Biosciences, Sutro Biopharma and Maze Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Solutions for biomarker discovery and diagnostic testing are provided.
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
Detailed competitors of ParAllele BioScience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Parallele Bioscience
Complete news archive for ParAllele BioScience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ParAllele BioScience
ParAllele BioScience was founded in 2001 and raised its 1st funding round 2 years after it was founded.
ParAllele BioScience is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
ParAllele BioScience is a funded company, having raised a total of $22.5M across 2 funding rounds to date.
ParAllele BioScience was focused on providing genetic discovery solutions to the life science research, pharmaceutical, and diagnostic sectors. Its products and services were based on the approach that leverages novel biochemical processes and discovers and analyze minute variations in the human genome which contribute to disease risk, prognosis, and drug response. It also had research collaborations with multiple large pharmaceutical companies and prestigious academic and government institutions. Its proprietary Molecular Inversion Probe assay, also known as MIP technology was used by many biotechnology companies including Affymetrix. MIP involves capture by circularization technique, wherein during hybridization with the target the probes get circularized, increasing the specificity and scalability of the assay. In 2005, Affymetrix acquired ParAllele.
ParAllele BioScience's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
ParAllele BioScience has 5 investors. Key investors include Abingworth, Affymetrix, Mohr Davidow Ventures, Index Ventures, and Versant Ventures.